Abstract
Tyrosine kinase inhibitors show great promise as clinical therapies, but small molecule inhibitors that are available in the clinic and under development bind to the adenosine triphosphate binding domain of the kinase, potentially limiting efficacy and selectivity. The development of antisense peptide inhibitors is a relatively unexplored area of research, and here we investigate inhibitory peptides specific for the Janus-associated kinase (JAK) family member, tyrosine kinase 2 (TYK2). We have developed peptides that are 2–3 times more selective for TYK2 than other JAK family members, with a TYK2 IC50 of 1.2 μM. In addition, TYK2 inhibitory peptides show specificity for TYK2-mediated functions over JAK1 functions in cell-based assays. These peptides provide a new tool for the development of specific peptide inhibitors for closely related tyrosine kinases.
Keywords: Antisense peptide, JAK, TYK2, tyrosine kinase.
Protein & Peptide Letters
Title:Design of a Peptide Inhibitor of Tyrosine Kinase 2
Volume: 21 Issue: 5
Author(s): Melissa G. Works, Benben Song, Patrick Kibler, Mary J. Tanga, Amit K. Galande and Annalisa D’Andrea
Affiliation:
Keywords: Antisense peptide, JAK, TYK2, tyrosine kinase.
Abstract: Tyrosine kinase inhibitors show great promise as clinical therapies, but small molecule inhibitors that are available in the clinic and under development bind to the adenosine triphosphate binding domain of the kinase, potentially limiting efficacy and selectivity. The development of antisense peptide inhibitors is a relatively unexplored area of research, and here we investigate inhibitory peptides specific for the Janus-associated kinase (JAK) family member, tyrosine kinase 2 (TYK2). We have developed peptides that are 2–3 times more selective for TYK2 than other JAK family members, with a TYK2 IC50 of 1.2 μM. In addition, TYK2 inhibitory peptides show specificity for TYK2-mediated functions over JAK1 functions in cell-based assays. These peptides provide a new tool for the development of specific peptide inhibitors for closely related tyrosine kinases.
Export Options
About this article
Cite this article as:
Works G. Melissa, Song Benben, Kibler Patrick, Tanga J. Mary, Galande K. Amit and D’Andrea Annalisa, Design of a Peptide Inhibitor of Tyrosine Kinase 2, Protein & Peptide Letters 2014; 21 (5) . https://dx.doi.org/10.2174/0929866520666131203101841
DOI https://dx.doi.org/10.2174/0929866520666131203101841 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Targeted Radiotherapy of Bone Malignancies
Current Drug Discovery Technologies Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome
Current Neurovascular Research Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Patents in Therapeutic Recombinant Protein Production Using Mammalian Cells
Recent Patents on Biotechnology ADAM8 in Allergy
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Pro-Inflammatory Molecules and Pharmacological Agents in Acute Pancreatitis and Sepsis
Inflammation & Allergy - Drug Targets (Discontinued) Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma
Current Cancer Drug Targets The New Era of Nutraceuticals: Beneficial Effects of Polyphenols in Various Experimental and Clinical Settings
Current Pharmaceutical Design Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews Angiotensin II: Role in Skeletal Muscle Atrophy
Current Protein & Peptide Science Agave (Agave spp.) and its Traditional Products as a Source of Bioactive Compounds
Current Bioactive Compounds Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Antiulcer and Antioxidant Activity of a Lectin from Mucuna pruriens Seeds on Ethanol- induced Gastropathy: Involvement of Alpha-2 Adrenoceptors and Prostaglandins
Current Pharmaceutical Design Subject Index to Volume 5
Current Drug Targets Pathological Role for Exocytotic Glutamate Release from Astrocytes in Hepatic Encephalopathy
Current Neuropharmacology